|ZFIN ID: ZDB-PUB-130208-6|
|Source:||Hum. Mol. Genet. 22(9): 1746-1754 (Journal)|
|Registered Authors:||Lin, Yung-Yao, Powell, Gareth, Stemple, Derek L., Wright, Gavin J.|
Animals; Cell Line, Tumor; Chromosome Mapping; Cohort Studies; Dystroglycans/metabolism
|PubMed:||23359570 Full text @ Hum. Mol. Genet.|
Several known or putative glycosyltransferases are required for the synthesis of laminin-binding glycans on alpha-dystroglycan (αDG), including POMT1, POMT2, POMGNT1, LARGE, Fukutin, FKRP, ISPD and GTDC2. Mutations in these glycosyltransferase genes result in defective αDG glycosylation and reduced ligand binding by αDG causing a clinically heterogeneous group of congenital muscular dystrophies, commonly referred to as dystroglycanopathies. The most severe clinical form, Walker-Warburg syndrome (WWS), is characterised by congenital muscular dystrophy and severe neurological and ophthalmological defects. Here, we report two homozygous missense mutations in the β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) gene in a family affected with WWS. Functional studies confirmed the pathogenicity of the mutations. First, expression of wildtype but not mutant B3GNT1 in human prostate cancer (PC3) cells led to increased levels of αDG glycosylation. Second, morpholino knockdown of the zebrafish b3gnt1 orthologue caused characteristic muscular defects and reduced αDG glycosylation. These functional studies identify an important role for B3GNT1 in the synthesis of the uncharacterised laminin-binding glycan of αDG and implicate B3GNT1 as a novel causative gene for WWS.